The oncology medicinal chemistry program focuses on targeted therapies (e.g., Vascular Disrupting Agents, Hsp90 inhibitors, Multi-Target Agents…) and the development of dual-drug payload combining two distinct mechanism of action for applications in ADC & ADDC. Other interests include the identification of small molecule drugs targeting tumor antigens in order to enhance the ability of the immune system to selectively recognize and attack cancer cells. Studies are also underway on the design of peptidic enzyme inhibitors (Pin1, cathepsin D inhibitors) as well as the PROTAC approach.